Ryan J. Watts - Feb 13, 2023 Form 4 Insider Report for Denali Therapeutics Inc. (DNLI)

Role
President and CEO, Director
Signature
/s/ Tyler Nielsen, by power of attorney
Stock symbol
DNLI
Transactions as of
Feb 13, 2023
Transactions value $
-$1,000,243
Form type
4
Date filed
2/15/2023, 06:01 PM
Previous filing
Feb 13, 2023
Next filing
Apr 24, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DNLI Common Stock Sale -$265K -8.82K -0.39% $30.09 2.24M Feb 13, 2023 See footnote F1, F2, F3, F4
transaction DNLI Common Stock Options Exercise $17K +25K +1.12% $0.68* 2.26M Feb 13, 2023 See footnote F4
transaction DNLI Common Stock Sale -$752K -25K -1.1% $30.08 2.24M Feb 13, 2023 See footnote F4, F5, F6
holding DNLI Common Stock 188K Feb 13, 2023 Direct F3, F7

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DNLI Stock Option (right to buy) Options Exercise $0 -25K -2.05% $0.00 1.2M Feb 13, 2023 Common Stock 25K $0.68 Direct F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units.
F2 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $29.95 to $30.24 per share. Upon request by the Commission staff, the Issuer, or a securityholder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3 Reflects the issuance of shares to the Watts Family 2015 Trust in connection with the vesting of 19,697 restricted stock units held by the Reporting Person.
F4 The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee.
F5 The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
F6 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $30.00 to $30.26 per share. Upon request by the Commission staff, the Issuer, or asecurityholder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F7 Includes 188,437 RSUs.
F8 The vesting of the shares subject to the option are contingent upon the achievement of certain performance metrics. 50% of the shares subject to the option vested on March 3, 2021, and 50% of the shares subject to the option will vest on the date the closing price of Issuer's Common Stock equals or exceeds $80.00 per share on NASDAQ for 90 consecutive trading days.